This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Study to Determine the Absorption, Distribution, Metabolism, and Excretion of LBH589

This study has been completed.
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals ) Identifier:
First received: May 10, 2007
Last updated: April 27, 2012
Last verified: April 2012
This single center study will help determine the absorption, metabolism, and excretion of LBH589 and to assess the safety and efficacy of LBH589 in advanced cancer patients for whom no standard therapy exists.

Condition Intervention Phase
Cancer Patients With Advanced Solid Tumors Including Lymphoma or Chronic Hematological Malignancies Drug: LBH589 Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open-label, Single Center, Study to Determine the Absorption, Distribution, Metabolism, and Excretion (ADME) of LBH589 After a Single Oral Administration of 20 mg (14C) LBH589 in Advanced Cancer Patients

Resource links provided by NLM:

Further study details as provided by Novartis ( Novartis Pharmaceuticals ):

Primary Outcome Measures:
  • Rates and routes of excretion of LBH589 and its metabolites in urine and feces following administration of a single oral dose of [14C] LBH589 [ Time Frame: during the first 8 days on study ]
    oral dose of [14C] LBH589

Secondary Outcome Measures:
  • Safety Efficacy

Enrollment: 4
Study Start Date: May 2007
Primary Completion Date: June 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: LBH589 Drug: LBH589
Other Name: Panobinostat


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion criteria

  • Histologically or cytologically confirmed cancer patients including solid tumors, lymphoma, or chronic hematological malignancies with progression on prior standard therapies.
  • Eastern Cooperative Oncology Group (ECOG) Performance Status of < 2
  • Normal renal and hepatic function

Exclusion criteria

  • Patients with central nervous system (CNS) involvement or brain metastases
  • Patients who have received chemotherapy, any investigational drug, undergone major surgery, or received wide field radiotherapy less than 4 weeks ago
  • Patients with congenital long QT syndrome or uncontrolled hypertension
  • Patients with a myocardial infarction or unstable angina within 6 months
  • Congestive heart failure
  • Impairment of gastrointestinal (GI) function
  • Use of any anti-cancer therapy
  • Female patients who are pregnant or breast feeding

Other protocol inclusion/exclusion criteria may apply.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00472368

United States, New York
Novartis Investigative Site
Buffalo, New York, United States, 14263
Sponsors and Collaborators
Novartis Pharmaceuticals
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
  More Information

Responsible Party: Novartis Pharmaceuticals Identifier: NCT00472368     History of Changes
Other Study ID Numbers: CLBH589B2108
Study First Received: May 10, 2007
Last Updated: April 27, 2012

Keywords provided by Novartis ( Novartis Pharmaceuticals ):
Advanced cancer
chronic hematological malignancies

Additional relevant MeSH terms:
Antineoplastic Agents
Histone Deacetylase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on June 22, 2017